Content and Quality of 10 000 Controlled Trials in Schizophrenia Over 60 Years
Content and Quality of 10 000 Controlled Trials in Schizophrenia Over 60 Years
复制标题
DOI：
10.1093/schbul/sbr140
复制
发表时间：
2013-01-01
影响因子：
6.6
通讯作者：
Adams, Clive E.
中科院分区：
文献类型：
--
作者：
Miyar, Jose;Adams, Clive E.
目的：对与精神分裂症患者治疗相关的干预试验的内容和质量进行最新的全面调查。设计：数据提取和分析来自科克伦精神分裂症组注册的10000个试验。主要结果指标：来源、出版类型和日期、来源国、语言、试验规模、干预措施和结果指标。结果如下：在过去十年中，与精神分裂症相关的试验数量大幅增加，报告的可获得性也有所改善。每年的试验数量正在增加（目前约为600/年），中国目前占年度总量的25%。由于多种出版物，审判报告的数量正在以更快的速度增加。药物试验仍然占主导地位（83%），尽管越来越多的研究正在评估心理疗法（21%）。试验仍然很小（中位数60人），并且经常使用新的未经验证的结果量表（2194个不同的量表，每五个试验中就有一个新的评级工具）。结论：一个更合作，务实，以病人为中心的方法是必要的，以产生更大的精神分裂症试验。更广泛的咨询和对所有相关观点的仔细考虑将导致对疾病患者及其家人或照顾者具有更大临床实用性和直接价值的试验。
Objective: To carry out an up-to-date comprehensive survey of the content and quality of intervention trials relevant to the treatment of people with schizophrenia. Design: Data were extracted and analyzed from 10 000 trials on the Cochrane Schizophrenia Group's Register. Main outcome measures: Source, type and date of publication, country of origin, language, size of trial, interventions, and outcome measures. Results: In the last decade, there has been a great increase in the number of trials relevant to schizophrenia and an improvement in the accessibility to reports. The number of trials per year is rising (currently similar to 600/year) with China now producing 25% of the annual total. The number of reports of trials is increasing at an even greater rate due to multiple publications. Drug trials still dominate (83%) although an increasing proportion of studies are now evaluating psychological therapies (21%). Trials remain small (median 60 people) and often employ new nonvalidated outcomes scales (2194 different scales were employed with every fifth trial introducing a new rating instrument). Conclusions: A more collaborative, pragmatic, and patient-centered approach is necessary to produce larger schizophrenia trials. Wider consultation and careful consideration of all relevant perspectives would result in trials with greater clinical utility and direct value to people with the illness and their families or carers.